We next treated the Hep3B HCC cell line with 10,058-F4, a c-MYC inhibitor, and the results showed that NFAT5 expression was increased at both the mRNA and protein levels after 48 h of treatment (Fig. 3h), suggesting that c-MYC inhibited NFAT5 expression by binding to the NFAT5 promoter. Here, NFAT5 is linked to hepatocellular carcinoma.